Management
Sales Team
 

Mission Statement

Our vision is to be a premier pharmaceutical company providing the most responsive, innovative, financially sound medicines through quality customer service and education.

About WraSer Pharmaceuticals

Based in Ridgeland, Mississippi, privately held WraSer Pharmaceuticals is an emerging pharmaceutical company that identifies, develops, and markets proprietary pharmaceutical products to physicians and pharmacies throughout the United States.

WraSer’s professional, results-oriented staff, combined with our strategic business alliances and innovative sales model have established WraSer as a pace setter in its market category.

Founded in 2002, WraSer Pharmaceuticals is committed to bringing proprietary products to market each year and expanding it sales force annually.

WraSer will continue to leverage its collective Otic Infections, Upper and Lower Respiratory, and Pain Management expertise to keep developing a portfolio of innovative, therapeutically safe and cost effective products.

A Brief Timeline

2002- WraSer Pharmaceuticals is founded by Heath Wray and Cole Smelser.

2002- WraSer Pharmaceuticals launches Vazol, Betavent, and Lusonex.

2003- WraSer Pharmaceuticals launches Vazol-D, Flutuss HC, and Lusonal.

2004- WraSer Pharmaceuticals launches Betatan.

2005- WraSer Pharmaceuticals launches its first dermatology products NuOx and  NuCort.  WraSer also launches Flutuss XP and Lusonex Plus.

2006- WraSer Pharmaceuticals launches its first suspension [12-Hr] products VazoBID and VazoTAN.  WraSer also launches its first pain product Levacet.

2007- WraSer Pharmaceuticals launches VazoTUSS HC suspension.

2008- WraSer Pharmaceuticals launches its first chewable tablet VazoTAB.  WraSer launches NuCort Lotion and agrees to co-promote FDA approved Halog®, Eurax®, and Exelderm® with Ranbaxy.

2009- WraSer Pharmaceuticals launches 3 new pain products.  FDA approved Xolox® for acute and chronic pain and FDA approved Trezix® for moderate to moderately severe pain.  WraSer also introduces Prodrin™ to its pain line for migraines.  WraSer Pharmaceuticals launches its first FDA approved product Cetraxal® for otic infections.  WraSer Pharmaceuticals establishes WraSer Dermatology a divison of WraSer Pharmaceuticals LLC to market its Dermatology line.

2009- WraSer Pharmaceuticals establishes WraSer Pain Management a divison of WraSer Pharmaceuticals LLC to market its Pain Management line.

2010- WraSer Pharmaceuticals enters into an agreement to Co Promote Cedax® Capsules with Pernix Theraputics adding another addition to its Primary Care line.  WraSer Pharmaceuticals receives FDA approval June 10th for Hydrocet®.

2011- WraSer Pharmaceuticals enters into an agreement to Co Promote Denavir® Cream with New American Therapeutics in the Primary Care specialty.  Please visit www.DENAVIR.com to find out more information about Denavir and New American Therapeutics (NATX).  WraSer Pharmaceuticals enters into an exclusive agreement to Co Promote Nalfon Capsules with Pedinol Pharmacal outside of the Podiatry specialty.  Please visit www.NALFON.com to find out more information about Nalfon and Pedinol Pharmacal.

2012- WraSer Pharmaceuticals licenses (benzphetamine hcl) 25 mg tablets from Truxton Pharmaceuticals.  WraSer Pharmaceuticals enters into an exclusive agreement for the marketing of Nalfon (fenoprofen calcium) 200 mg and 400 mg capsules.